Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1410-1418

  Bae, S H ^a   Jung, E S ^a   Park, Y M ^a   Kim, B S ^a   Kim, B K ^a   Kim, D G ^a   Ryu, W S ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOLE DERIVATIVE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER STAGING; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; METASTASIS; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOENZYMES; LIVER; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0034905269     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Epidemiological characteristics and risk factors of hepatocellular carcinoma
2. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
3. Differential expression of cyclooxygenase 2 in human colorectal cancer
4. Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis
5. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas
6. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma
7. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma
8. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma
9. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
10. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers
11. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
12. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
13. Suppression of intestinal polyposis in Apc 8716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
14. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
15. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
16. Human cyclooxygenase-2 cDNA
17. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
18. Aspirin and the potential role of prostaglandins in colon cancer
19. Eicosanoids and the gastrointestinal tract
20. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: Possible physiological and therapeutic implications
21. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
22. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells
23. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: Regulation of COX-2 by butyrate
24. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation
25. Cyclooxygenase-2 expression in hepatocellular carcinoma
26. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment
27. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions
28. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and downregulates bcl-2 expression in LNCaP cells
29. Differences in ethidium bromide and 4′-6-diamidino-2-phenylindole staining profiles with regard to DNA fragmentation during apoptosis
30. The role of cyclooxygenases in inflammation, cancer, and development
31. Liver cancer
32. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma
33. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
34. 1 phase of the cell cycle by indomethacin
35. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
36. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
37. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
38. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
39. Cyclooxygenase regulates angiogenesis induced by colon cancer cells